Trial Profile

The Diagnostic Value and Influencing Factors of Tegoprazan Test for Gastro-esophageal Reflux Disease

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tegoprazan (Primary)
Indications Gastro-oesophageal reflux
Focus Diagnostic use

Most Recent Events

17 Jun 2025 New trial record
26 May 2025 Results (n=98, 91 for weeks 1 and 2 respectively) assessing mid-term report from this study for the accuracy of the diagnosis of gastro-esophageal reflux disease (GERD) through tegoprazan treatment trials, and to analyze factors that may influence test accuracy, published in the BMC Gastroenterology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com